New findings shed light on the key #microbes that protect against recurrent #Clostridiodes difficile infection and #MultipleSclerosis, pointing to future treatment opportunities with live #biotherapeutics. Read more: mshs.co/3Q9ZZdH #Immunology

Happy to share the latest preprint from the Beth Stadtmueller - an incredible effort by recent PhD student @Sonya31397350! Engineered Secretory Immunoglobulin A provides insights on antibody-based effector mechanisms targeting Clostridiodes difficile biorxiv.org/content/10.110…

🆕🔥Our study on C. difficile infections among allogeneic HCT recipients in the framework of the Swiss Transplant Cohort Study🇨🇭Bone Marrow Transplantation The EBMT A short summary 🔽1/5 #IDTwitter nature.com/articles/s4140…

Could a Breath biopsy be used for C. difficile diagnosis in the future? Breath Biopsy and Discovery of Exclusive Volatile Organic Compounds for Diagnosis of Infectious Diseases ncbi.nlm.nih.gov/pmc/articles/P…

Doxycycline tied to lower risk for C. difficile in pneumonia patients medicalxpress.com/news/2023-11-d…

Grat to Jannie and CMAT for this study on bacterial and fungal microbiome interactions in patients colonized or infected with Cdiff. EurFMT Clinical Microbiology and Infection Wiep Klaas Smits oaepublish.com/articles/mrr.2…

C. Diff: Professors Suggest Inflammation, Not Bacteria Should be Targeted bit.ly/4akb9UH #CDiff #ClostridioidesDifficile

The role of gut fungi in #Clostridioides difficile infection sciencedirect.com/science/articl… #OpenAccess #mycology #Cdiff

Update on Microbiota-derived therapies for recurrent Clostridioides difficile infections, 2023 sciencedirect.com/science/articl…

Genetic variation in the human leukocyte antigen region confers susceptibility to Clostridioides difficile infection nature.com/articles/s4159…

Fecal Microbiota Transplantation: Information for the Pediatrician publications.aap.org/pediatrics/art…

Have you seen this new ACG monograph on microbiome therapeutics? ✅ Essential aspects of methods for analyzing the microbiome ✅ Present and future therapeutics for C. difficile ✅ Non-prescription therapeutics 👉 journals.lww.com/ajg/toc/2024/0…

Clindamycin attacking the normal flora 🥊 x.com/Yoda4ever/stat…

Pleased to share this publication on vaccine potential of Salmonella against C. difficile in a mouse model: a collaboration with Brian Ward and Ph. D. student Kaitlin Winter MIMM McGill and my group Institut national de la recherche scientifique Infectiopole INRS. Out in Microbiol. Spectrum: journals.asm.org/doi/10.1128/sp…

In Clinical Infectious Diseases, Pablo Okhuysen, MD, FACP, FIDSA, and colleagues aim to confirm the superiority of ridinilazole over vancomycin on Sustained Clinical Response and recurrent CDI as reported in a Phase II Study. Read: idsajournals.link/2OufYh

A new antimicrobial peptide designed based on Clostridioides difficile IF1 shows broad-spectrum inhibitory activities against C. difficile and other bacterial strains. journals.asm.org/doi/10.1128/sp…

Friday Celebrations! Chenlin Hu, PhD and Kevin Garey published a review of microscopy methods for C. difficile in Anaerobe! 🔬🦠 Check it out ⬇️⬇️ doi.org/10.1016/j.anae… Anaerobe Society UH Pharmacy

🌟And the publications keep coming!🌟 Check out our labs most recent work on ibezapolstat activity against MDR C. difficile strains ⬇️⬇️ doi.org/10.1128/aac.01… TLDR: IBZ bactericidal activity was similar to the MIC and maintained in wild-type and non-susceptible strains.

It's not just about age anymore. #Clostridioidesdifficile infection is reaching beyond traditional risk groups. #guthealth #Cdiff

🆕️🔥Multicenter cohort study included adults with C. difficile infection Clinical Infectious Diseases Vancomycin MIC >2 μg/mL in Clostridioides difficile was associated with decreased odds of 30-day sustained clinical response & lower 14-day initial cure rates #IDXposts academic.oup.com/cid/article-ab…